Daiichi Sankyo Is Not A Buy Now [Seeking Alpha]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Seeking Alpha
Daiichi Sankyo ( OTCPK:DSNKY The prospect to which I refer is the DS-8201 drug, marketed under the brand name Enhertu, which targets HER2 metastatic breast cancer cells. It is an antibody-drug conjugate, or ADC - a type of drug that targets cancer cells while sparing healthy cells. FDA approval for Enhertu was granted Daiichi Sankyo clearly has great confidence in Enhertu going forward. Company president and CEO Sunao Manabe has declared cut in March 2019 AZN The terms of the deal are as follows: AstraZeneca will pay Daiichi Sankyo $6.9 billion and receive a share of Enhertu sales, Daiichi Sankyo will receive revenue from sales in Japan, Europe, and the U.S. while AstraZeneca get the rest, and development costs will be split evenly. The fact that Daiichi Sankyo has structured the deal so favorably to them, and that AstraZeneca was happy to accept that deal, underlines that Daiichi Sankyo has something special here. If Manabe's prediction does come to pass, shareholders will be happy t
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and "AP" Rated¹ [Yahoo! Finance]Yahoo! Finance
- American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and "AP" Rated¹PR Newswire
- Arbitration Dispute Between Daiichi Sankyo and Seagen Ends [Yahoo! Finance]Yahoo! Finance
- Arbitration Dispute Between Daiichi Sankyo and Seagen EndsBusiness Wire
- Merck, Daiichi lung cancer therapy rejected in U.S. [Seeking Alpha]Seeking Alpha